In a 37-year-old woman on lithium for 10 years who presents with polyuria and polydipsia, serum sodium 145 mmol/L, serum osmolality 306 mOsm/kg, urine osmolality 225 mOsm/kg, and creatinine 1.10 mg/dL, and wishes to remain on lithium, what is the next appropriate management step?

Lithium-Induced Nephrogenic Diabetes Insipidus: Management While Continuing Lithium

You should perform a water deprivation test with desmopressin (DDAVP) to confirm nephrogenic diabetes insipidus, then initiate amiloride 5-10 mg daily combined with hydrochlorothiazide 25 mg daily while maintaining lithium therapy. 1

Diagnostic Confirmation

Your patient's presentation is classic for lithium-induced nephrogenic diabetes insipidus (NDI):

• Polyuria and polydipsia after 10 years of lithium exposure
• Inappropriately dilute urine (urine osmolality 225 mOsm/kg) despite elevated serum osmolality (306 mOsm/kg) and high-normal serum sodium (145 mmol/L)
• Preserved renal function (creatinine 1.10 mg/dL)

The FDA drug label explicitly warns that chronic lithium therapy is associated with diminished renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus with polyuria and polydipsia 1. This occurs in 20-40% of long-term lithium users 2.

Before initiating treatment, perform a formal water deprivation test with DDAVP administration to definitively distinguish NDI from central diabetes insipidus (which, though rare, has been reported with lithium) 3, 2. In NDI, urine osmolality will remain <300 mOsm/kg even after DDAVP, confirming vasopressin resistance 4.

Pharmacological Management Strategy

Since the patient wishes to continue lithium, the evidence supports a specific dual-diuretic approach:

First-Line: Amiloride + Thiazide Combination

Start amiloride 5 mg daily (can increase to 10 mg if needed) plus hydrochlorothiazide 25 mg daily 5, 6. This paradoxical use of diuretics in polyuria works through distinct mechanisms:

• Amiloride blocks epithelial sodium channels (ENaC) in the collecting duct, reducing lithium entry into principal cells and thereby decreasing lithium-induced aquaporin-2 downregulation 6
• Thiazide diuretics induce mild volume depletion, increasing proximal tubular sodium and water reabsorption, which reduces fluid delivery to the collecting duct 7, 5

Recent case reports demonstrate this combination can reduce urine output from 15 L/day to normal levels 5. The 2025 consensus statement on nephrogenic diabetes insipidus recommends thiazides combined with prostaglandin synthesis inhibitors for symptomatic patients 7.

Critical Monitoring Requirements

Monitor closely during the first 2 weeks:

• Serum sodium, potassium, and lithium levels every 5-7 days initially 8
• Weight and fluid balance daily to detect hyponatremia (patients maintaining high fluid intake after starting diuretics can develop dangerous hyponatremia) 7
• Serum creatinine to ensure no acute kidney injury

The FDA label emphasizes that patients on lithium with NDI "should be carefully managed to avoid dehydration with resulting lithium retention and toxicity" 1.

Lithium Dose Optimization

Consider reducing lithium dose if currently >1000 mg/day. Recent research shows that higher lithium daily doses are independently associated with higher urine output and elevated vasopressin levels 3. In a 2022 study, all patients receiving ≥1400 mg/day had elevated vasopressin levels, and lithium dose was the strongest predictor of 24-hour urine output (β 0.49, P = 0.005) 3.

However, do not reduce lithium dose if it compromises psychiatric stability. The 2007 AACAP guidelines emphasize that maintenance therapy benefits must outweigh risks, decided case-by-case 8.

Dietary Modifications

Implement controlled sodium and protein intake (aim for <2-3 g sodium/day). Daily osmolar intake was independently associated with higher 24-hour urine output in lithium-treated patients 3. This reduces the renal solute load requiring excretion.

Recommend fluid intake of 1-1.5 L/day once diuretics are started, adjusting based on serum sodium levels 7.

Long-Term Monitoring Protocol

Every 3-6 months, measure:

• Lithium levels
• Serum creatinine and electrolytes
• Thyroid function (TSH)
• Urinalysis 8

Annually, consider:

• 24-hour urine collection to quantify polyuria
• Renal ultrasound to assess for microcystic changes (common in lithium-induced CKD) 6

When to Discontinue Lithium

Discontinue lithium only if:

• Progressive CKD develops (>30% decline in GFR)
• Severe, refractory polyuria persists despite maximal medical management
• Recurrent episodes of lithium toxicity occur
• Psychiatric condition can be safely managed with alternative agents

The 2026 review emphasizes that "the decision to discontinue lithium is challenging, and benefits versus risks must be carefully weighed" 6. Substituting lithium may improve objective measures of renal tubular dysfunction more than dose reduction 9, but psychiatric relapse risk must be considered.

Common Pitfalls to Avoid

1. Don't assume all polyuria is NDI – rare cases of central diabetes insipidus with lithium have been reported 2
2. Don't start diuretics without close monitoring – rapid development of hyponatremia can occur if fluid intake remains high 7
3. Don't ignore thyroid function – lithium-induced hypothyroidism can coexist and worsen symptoms 8
4. Don't delay intervention – chronic NDI can progress to irreversible CKD with glomerular and interstitial fibrosis 1